IQVIA HOLDINGS INC.
IQVIA HOLDINGS INC. (IQV) Stock News
The latest IQV headlines and market coverage — 4 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
IQVIA Holdings is expected to report Q3 2026 earnings on October 27, with consensus estimates of $3.24 EPS (up 8% YoY) and $4.36B in revenues (up 6.4% YoY). However, recent analyst revisions have turned slightly bearish, resulting in a negative Earnings ESP of -0.09%, making it difficult to predict an earnings beat despite the company's strong historical track record of beating estimates in the last four quarters.
- Zacks Investment Research·
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.
- Zacks Investment Research·
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.
- The Motley Fool·
An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion
IQVIA CEO Ari Bousbib sold approximately 106,000 shares worth $26.1 million through an exercise-and-sell of expiring stock appreciation rights. The sale follows a strong Q2 earnings report with record clinical bookings of $3.15 billion and 8.7% revenue growth. Bousbib maintains a substantial 1.4 million share position, indicating the sale was routine calendar management rather than a bearish signal.